YM BioSciences Pain Treatment Study Disappoints
Posted on: Thursday, 28 September 2006, 06:00 CDT
YM BioSciences has said its phase II study of AeroLEF for the treatment of pain in post-surgical patients has failed to reach expected results.
Initial results from the study show that AeroLEF provided benefit compared to placebo. However, the difference in effectiveness between the placebo and treatment groups has not yet reached the study endpoint and therefore YM BioSciences will continue as planned to enroll the original target of patients.
"This preliminary review indicates that we should continue to advance the AeroLEF phase IIb study to full enrollment," said David Allan, chairman and CEO of YM BioSciences.
AeroLEF is a unique, inhaled-delivery for the treatment of moderate to severe acute pain, including cancer pain.
The primary endpoint for this study is to asses the difference between pain intensity and pain relief during the first four hours after the start of the initial dose. Secondary endpoints include time to effective pain relief, as well as six safety endpoints.
Source: Datamonitor
Related Articles
- SRI International and F. Hoffmann-La Roche Launch Translational Medicine Collaboration to Study Methods and Treatments Associated with Cognitive Deficits Across Neuropsychiatric Disorders
- Array BioPharma Reports Positive Results From Phase II Dental Pain Study
- 7-year Neck Pain Study Sheds Light on Best Care
- One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
- Nutra Pharma Announces Positive Results of ReceptoPharm Pain Study
- Tibotec Therapeutics Announces Initiation of the Largest U.S. Clinical Study Examining HIV Treatment in Treatment-Experienced Adult Women
- Nutra Pharma Announces Publication of Positive Results of ReceptoPharm Pain Study
- Pharmos Begins Dosing in New Phase IIa Pain Study
- Symbollon Provides Update on IoGen Phase III Pain Study
- Javelin Enrolls First Patient In Pivotal Phase III Postop Pain Study of Dyloject(TM)
 |
 |
User Comments (0)
RSS Feeds